Table 3 Increased risk of CMDs in individuals with high IBD-specific MRS
IBD-specific MRS | Association between the high MRS group and CMD development | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
All | High-MRS group | Low-MRS group | vs. Control | vs. CMD-free IBD | ||||||
Median (range) | n | Median (range) | n (%) | Median (range) | n (%) | OR (95% CI) | P-value | OR (95% CI) | P-value | |
Control | −1.18 (−23.21 to 6.23) | 75 | 1.29 (0.64 to 6.23) | 19 (25.3%) | −2.23 (−23.21 to 0.62) | 56 (74.7%) | 1 (reference) | – | – | – |
CMD-free IBD | 0.76 (−14.38 to 21.02) | 196 | 1.23 (0.63 to 21.02) | 106 (54.1%) | −0.56 (−14.38 to 0.63) | 90 (45.9%) | 3.4 (1.7 to 6.4) | 2.92 ×10−4 | 1 (reference) | – |
CMD-affected IBD | 1.21 (−0.88 to 33.88) | 29 | 1.23 (0.86 to 33.88) | 25 (86.2%) | 0.18 (−0.88 to 0.48) | 4 (13.8%) | 23.1 (5.3 to 101.2) | 3.20 ×10−5 | 5.04 (1.7 to 15.4) | 4.64 ×10−3 |
